Click on image to view larger version.

Figure 3 Residual platelet function assessed by 20 µM ADP induced aggregation (top) and flow cytometry analysis of fibrinogen-platelet binding (bottom) in 10 patients who received eptifibatide followed by abciximab and in five patients who received only abciximab. Results are expressed as mean ± SEM percent of baseline aggregation. A significant decrease in platelet function after the abciximab bolus was evidenced only by the fibrinogen-binding assay. Open square = eptifibatide-abciximab group; solid circle = abciximab control group. Abx = abciximab; Ept = eptifibatide; Maint = maintenance.